Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-04-20

Clinical Trial Update: Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC) [Phase 2]

View source ↗

Summary

Phase 2 trial comparing gemcitabine plus cisplatin vs gemcitabine plus carboplatin in triple-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CARBOPLATIN (Carboplatin)
  • CISPLATIN (cisplatin)
  • Gemcitabine (Gemcitabine)

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN